Company intelligence / Profile preview
NovaBridge Biosciences
United States
- Ownership
- Public · NBP
- Development stage
- Other
01
Overview
NovaBridge Biosciences (formerly I-Mab) is a global biotech platform company with a pipeline that includes advanced clinical-stage assets targeting oncology and ophthalmology. Key programs such as VIS-101 (bifunctional biologic, Phase 2 for wet AMD/DME; expected Phase 3-ready 2026), Givastomig (bispecific antibody, Phase 1b for gastric cancer), and Uliledlimab (anti-CD73, Phase 2 oncology) show promising early to mid-stage clinical results, with plans for global Phase 2 trials and strategic expansion in Asian and global markets[4][6][9].
- Therapeutic areas
- OncologyOphthalmology
- Modalities
- Bifunctional biologicBispecific antibodyMonoclonal antibody
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Financials
- Market cap
- $196M
- Total revenue
- $0
- Enterprise value
- $9.6M
Beyond the preview
Go deeper on NovaBridge Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NovaBridge Biosciences.